News

 
SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease
Read More
 
SiSaf Ltd utilizes Intoolab’s Tzager AI Platform
Read More
 
SiSaf Ltd Announces US$13.2 Million Series B Financing
Read More
 
Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium
Read More

Cookies

This website uses cookies. By proceeding navigating on this page, you agree to the use of the cookies according to the terms of our Privacy Policy Find out more.